Alessandro Antonelli

University of Pisa, Italy

  • Orcid: 0000-0002-5211-6342
  • Publications: N/A
  • Citations: N/A
  • Keywords: Thyroid, thyroid cancer, autoimmune thyroid disorders, chemokines
Short Bio
  • Prof. Alessandro Antonelli is currently Director of the Immuno-Endocrine Section of Internal Medicine, Head Laboratory of Primary Human Cells and Full Professor in the Department of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy. He is qualified in Internal Medicine, Endocrinology and Oncology. He has been chairman and invited speaker in international congresses and has given lectures in European and American Universities. He is member of international scientific associations (The Endocrine Society, European Thyroid Association, American Thyroid Association, Royal Society of Medicine, Italian Endocrine Association, etc.). He studied the therapeutic and immunomodulatory effect of intravenous immunoglobulin administration in patients with thyroid associated ophthalmopathy, and other autoimmune diseases. He first showed the presence of anti-CD38 autoantibodies in Caucasian patients with type 1, or 2 diabetes, or with chronic thyroiditis or Graves' disease. He showed an association between chronic hepatitis C infection, or mixed cryoglobulinemia, with thyroid autoimmunity, thyroid papillary cancer and diabetes, and studied the immunopathogenesis of this association, and of chemokines secretion. Furthermore, he studied the association of thyroid autoimmune disorders with different organ specific autoimmune disorders (autoimmune gastritis, type 1 diabetes, etc.) or systemic autoimmune diseases (LES, systemic sclerosis, psoriatic arthritis, etc.). He demonstrated the importance of interferon gamma inducible chemokines (CXCL10, CXCL9, CXCL11 etc), and of Th2 chemokine (CCL2) in the pathogenesis of autoimmune thyroiditis, Graves' disease and ophthalmopathy, type 1 diabetes, systemic sclerosis, hepatitis C and mixed cryoglobulinemia. He studied the effects of cytokines (interferons, TNFalpha, etc), and the production of chemokines in primary human cells from Graves’ disease and ophthalmopathy, cryoglobulinemia, and systemic sclerosis. First showed the effects of new tyrosine kinases inhibitors for the treatment of thyroid carcinoma in primary human thyroid cancer cells. His researches have been published in more than 410 articles on International journals with IF (IF>1700; H index 80).